Patents Examined by Patricia A. Duffy
  • CD40L-Fc fusion polypeptides and methods of use thereof
    Patent number: 10975155
    Abstract: Provided herein is a CD40L-Fc fusion protein and methods of using the fusion protein in the treatment of cancer comprising administering the CD40L-Fc fusion protein or the CD40L-Fc fusion protein in combination with one or more immune checkpoint inhibitors (e.g., an anti-CTLA4 antibody, anti-PD-L1 antibody).
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: April 13, 2021
    Assignee: MEDIMMUNE, LLC
    Inventors: Manuel Baca, Stacey Drabic, Peter Emtage, Ronald Herbst
  • Composition for topical use based on a carnosine-magnesium complex
    Patent number: 10973868
    Abstract: The present disclosure relates to a composition comprising a carnosine-magnesium complex. The composition is designed to be applied to the skin and causes an increase in carnosine levels in the body. The topical 5 composition comprising a carnosine-magnesium complex has the effect of improving an athlete's physical performance and may be effective for the treatment of a variety of medical conditions. Also disclosed is a method for preparing the carnosine-magnesium complex.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: April 13, 2021
    Inventors: Chad Macias, Tim Sharpe, Massimo Ferrari
  • Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
    Patent number: 10966931
    Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: April 6, 2021
    Assignee: JAZZ PHARMACEUTICALS, INC.
    Inventors: Clark Allphin, James Pfeiffer
  • Surfactant-free, water-free formable composition and breakable foams and their uses
    Patent number: 10967063
    Abstract: A substantially surface active agent-free and foam adjuvant-free composition which includes a hydrophobic solvent, a wax and a propellant. A substantially surface active agent-free and foam adjuvant-free composition, further comprising, a tetracycline antibiotic, or one or more other active agents. A method of treatment, using a substantially surface active agent-free and substantially foam adjuvant-free composition.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: April 6, 2021
    Assignee: Vyne Therapeutics Inc.
    Inventors: Dov Tamarkin, Elana Gazal, Irakliy Papiashvili, Yohan Hazot, David Schuz, Rita Keynan
  • Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
    Patent number: 10959956
    Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: March 30, 2021
    Assignee: JAZZ PHARMACEUTICALS, INC.
    Inventors: Clark Allphin, James Pfeiffer
  • Human antibodies to hemolysin A toxin
    Patent number: 10940211
    Abstract: The present invention provides antibodies that bind to Staphylococcus aureus Hemolysin A toxin, and methods of use. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Hemolysin A. The antibodies of the invention are useful for inhibiting or neutralizing Hemolysin A activity, thus providing a means of preventing or treating a Hemolysin A-related disease or disorder such as S. aureus infection. In some embodiments, the antibodies of the present invention are used in treating at least one symptom or complication of a S. aureus infection.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: March 9, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Alida Coppi, Peter Mason, William Olson
  • Anti-BCMA polypeptides and proteins
    Patent number: 10925969
    Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize B-Cell Maturation Antigen (BCMA) are disclosed. Chimeric antigen receptors (CARs), anti-BCMA binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer and methods of treating or preventing cancer are also disclosed.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: February 23, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Service, Sanford Research
    Inventors: Ira H. Pastan, Tapan Bera, Satoshi Nagata, Tomoko Ise, Yasuhiro Abe
  • Propynylaminoindan transdermal compositions
    Patent number: 10918607
    Abstract: Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix which includes the propynylaminoindan, a pressure sensitive adhesive that includes an acrylate copolymer and a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions.
    Type: Grant
    Filed: October 25, 2013
    Date of Patent: February 16, 2021
    Assignee: Teikoku Pharma USA, Inc.
    Inventors: Richard D. Hamlin, Amit Jain, Jianye Wen
  • Hydrocolloid-based skin treatment
    Patent number: 10912739
    Abstract: The present technology relates generally to devices for treatment of skin and skin conditions, as well as methods for preparing the devices and methods of treatment using the devices. Suitably, the devices comprise a hydrocolloid dressing and one or more active agents, wherein the amount of the active agent(s) does not reduce the absorption properties of the hydrocolloid dressing.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: February 9, 2021
    Assignee: PEACE OUT INC.
    Inventor: Enrico Frezza
  • Use of beta-1,3-glucan for modulating immune function and treating intestinal inflammation
    Patent number: 10912794
    Abstract: The present application relates to beta-1,3-glucan and uses thereof to modulate immunity in the human body. Also provided are methods for treatment and/or prevention of high cholesterol, diabetes, and allergies. Also provided are methods for treatment and/or prevention of intestinal inflammation.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: February 9, 2021
    Assignee: KEMIN INDUSTRIES, INC.
    Inventors: Geoffrey Paul Horst, Robert Bernard Levine
  • Magnesium phosphate hydrogels
    Patent number: 10875772
    Abstract: A hydrogel comprising a colloidal suspension of MIXMIIYPZ two-dimensional nanocrystals in water, wherein MI is Na+ and/or Li+, MII is Mg2+ or a mixture of Mg2+ with one or more Ni2+, Zn2+, Cu2+, Fe2+ and/or Mn2+, P is a mixture of dibasic phosphate ions (HPO42?) and tribasic phosphate ions (PO43?), X ranges from about 0.43 to about 0.63, Y ranges from about 0.10 to about 0.18, Z ranges from about 0.29 to about 0.48, X, Y, Z being mole fractions, is provided.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: December 29, 2020
    Assignee: INVICARE INC.
    Inventors: Faleh Tamimi Marino, Ashwaq Ali Al-Hashedi, Marco Laurenti, Ahmed Ebraheem Al Subaie, Mohamed-Nur Abdallah, Iskandar Tamimi Marino
  • Compositions for treatment of heart failure in dogs
    Patent number: 10874618
    Abstract: The invention relates to a new fixed dose combination of benazepril with pimobendan.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: December 29, 2020
    Assignee: Elanco Tiergesundheit AG
    Inventors: Jernej Grmas, Zdenka Jerala-Strukelj, Sebastjan Reven
  • Method for producing an isolated monoclonal antibody specifically binding to a glycolipid antigen of
    Patent number: 10870669
    Abstract: The present invention provides a novel glyceroglycolipid produced by Mycoplasma pneumoniae. The glyceroglycolipid can be used as a diagnostic marker for a disease caused by Mycoplasma pneumoniae.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: December 22, 2020
    Assignee: M BIO TECHNOLOGY INC.
    Inventors: Kazuhiro Matsuda, Yuko Shingu
  • Personal care compositions
    Patent number: 10849839
    Abstract: A personal care formulation comprising an active compound is operable to reduce the surface friction of hair fibres and promoting inter-fibre movement. The active compound is the reaction product of a fatty acid and a polyamine. The use of the active compound in a personal care formulation works as a friction modifier operable to reduce the surface friction of hair fibres. The invention extends to the active compound and a method of reducing hair-fibre surface friction.
    Type: Grant
    Filed: July 3, 2012
    Date of Patent: December 1, 2020
    Assignee: Croda International Plc
    Inventors: Michael Christopher Hindley, David John Freeman, James Prodger, Sean Philip Nigel Rouse
  • Effective hair styling compositions and processes
    Patent number: 10828246
    Abstract: This disclosure relates to hair styling compositions and processes, and more particularly to compositions for disentangling or crosslinking hair that are useful in hair styling processes.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: November 10, 2020
    Assignee: NUtech Ventures
    Inventors: Yiqi Yang, Helan Xu, Kaili Song
  • Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
    Patent number: 10813885
    Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: October 27, 2020
    Assignee: JAZZ PHARMACEUTICALS, INC.
    Inventors: Clark Allphin, James Pfeiffer
  • Streptococcal GlcNac-lacking gylcopolypeptides, cell wall carbohydrates, vaccines, and methods for making and using them
    Patent number: 10780155
    Abstract: In alternative embodiments, the invention provides vaccines, pharmaceutical compounds and formulations for diagnosing, preventing, treating or ameliorating Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections. In alternative embodiments, the invention provides compositions such as diagnostic tests, assays, immunoassays and test strips, and methods, for detecting or diagnosing the presence of a Streptococcal infection, e.g., Group A Streptococcus (GAS), Group C Streptococcus (GCS), or Group A Streptococcus (GGS), infections, or other pathogenic Streptococcus infections.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: September 22, 2020
    Assignee: The Regents of the University of California
    Inventors: Victor Nizet, Nina van Sorge
  • Immunogenic compositions against
    Patent number: 10772946
    Abstract: The invention relates to a conjugate of a saccharide covalently bound to a carrier protein, wherein the saccharide comprises repetitive units of 1,5 ribitol phosphate in which all the ribitol residues are substituted by N-acetyl D-glucosaminyl residues at the 4-position, and wherein said N-acetyl D-glucosaminyl residues are exclusively in anomeric configuration ? or are exclusively in anomeric configuration ? and wherein the carrier protein provides at least one epitope to the conjugate which is recognized by T helper lymphocytes.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: September 15, 2020
    Assignee: SANOFI PASTEUR
    Inventors: Pierre-Alexandre Driguez, Nathalie Guillo, Bachra Rokbi, Noëlle Mistretta, Philippe Talaga
  • Modified Fab region-binding peptide
    Patent number: 10774115
    Abstract: A first Fab region-binding peptide includes an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 5 with substitution of one or more amino acid residues at the 17th position and the 36th position, wherein an acid dissociation pH thereof is shifted to a neutral side. A second Fab region-binding peptide further includes deletion, substitution and/or addition of one or more amino acid residues at positions other than the 17th position and the 36th position. A third Fab region-binding peptide includes an amino acid sequence with a sequence identity of 80% or more to the amino acid sequence of the first Fab region-binding peptide.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: September 15, 2020
    Assignee: KANEKA CORPORATION
    Inventor: Shinichi Yoshida
  • Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
    Patent number: 10758488
    Abstract: Controlled release dosage forms are described herein. The controlled release formulations described herein provide prolonged delivery of high dose drugs that are highly water soluble and highly hygroscopic. In specific embodiments, controlled release dosage forms for delivery of a drug selected from GHB and pharmaceutically acceptable salts, hydrates, tautomers, solvates and complexes of GHB. The controlled release dosage forms described herein may incorporate both controlled release and immediate release formulations in a single unit dosage form.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: September 1, 2020
    Assignee: JAZZ PHARMACEUTICALS, INC.
    Inventors: Clark Allphin, James Pfeiffer